The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Chongzhen Guo
Chengda Yan
Lianyue Qu
Rongrong Du
Jianyang Lin
机构：
[1] The First Hospital of China Medical University,Department of Pharmacy
[2] China Medical University,School of Pharmaceutical Science
来源：
Archives of Gynecology and Obstetrics | 2021年 / 303卷
关键词：
Angiogenesis inhibitors; Ovarian cancer; Progression-free survival; Overall survival; Toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：285 / 311
页数：26
相关论文
共 50 条
  • [21] The role of angiogenesis inhibitors re-challenge in colorectal cancer previously treated with bevacizumab: a meta-analysis of randomized controlled trials
    Xiong, Y. -X.
    Ren, L.
    Wang, Z. -Q.
    Huang, X. -W.
    Zhou, Y. -J.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (07) : 1489 - 1494
  • [22] Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Wang, Yi
    Du, Xianling
    Xin, Hongqiang
    Xu, Ruimin
    CURRENT CANCER DRUG TARGETS, 2024, 24 (09) : 941 - 951
  • [23] Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials
    Sun, Guojuan
    Liu, Yi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [24] Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis
    Wang, Jin-feng
    Zhao, Lan-bo
    Bin, Ya-di
    Zhang, Kai-lu
    Sun, Chao
    Wang, Yi-ran
    Feng, Xue
    Ji, Jing
    He, Li-song
    Chen, Fang-yao
    Li, Qi-ling
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Ye, Ziqi
    Yang, Wenchao
    Xuan, Bixia
    Li, Xiaofang
    He, Jiana
    Si, Haiyan
    Ma, Wenhua
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [26] Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials
    Li, J.
    Zhou, L.
    Chen, X.
    Ba, Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09) : 673 - 683
  • [27] Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials
    J. Li
    L. Zhou
    X. Chen
    Y. Ba
    Clinical and Translational Oncology, 2015, 17 : 673 - 683
  • [28] Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis
    Yanling Feng
    He Huang
    Ting Wan
    Chuyao Zhang
    Chongjie Tong
    Jihong Liu
    Advances in Therapy, 2019, 36 : 3368 - 3380
  • [29] Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis
    Feng, Yanling
    Huang, He
    Wan, Ting
    Zhang, Chuyao
    Tong, Chongjie
    Liu, Jihong
    ADVANCES IN THERAPY, 2019, 36 (12) : 3368 - 3380
  • [30] Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials
    Marchetti, C.
    De Felice, F.
    Di Pinto, A.
    D'Oria, O.
    Aleksa, N.
    Musella, A.
    Palaia, I.
    Muzii, L.
    Tombolini, V.
    Panici, P. Benedetti
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 125 : 30 - 34
12345